Translational medicine perspective in development of disease modifying therapies for Alzheimer's disease: biomarkers to buy down the risk

Authors

  • Hong I. Wan,

    Corresponding author
    1. Clinical Translational Medicine, Wyeth Research, Collegeville, Pennsylvania
    • Clinical Translational Medicine, Wyeth Research, Collegeville, PA 19426
    Search for more papers by this author
  • Orest Hurko,

    1. Discovery Translational Medicine, Wyeth Research, Collegeville, Pennsylvania
    Search for more papers by this author
  • Mark Day,

    1. Discovery Translational Medicine, Wyeth Research, Collegeville, Pennsylvania
    Current affiliation:
    1. School of Medical Sciences, University of Aberdeen, IMS Building, Foresthill, Aberdeen AB25 2ZD, United Kingdom
    Search for more papers by this author
  • J. Lynn Rutkowski

    1. Clinical Translational Medicine, Wyeth Research, Collegeville, Pennsylvania
    Current affiliation:
    1. Biomedical Research Institute, Ninewells Hospital & Medical School, Dundee DD1 9SY, United Kingdom
    Search for more papers by this author

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common cause of age-related dementia. Currently available pharmacologic therapies, including acetylcholinesterase (AChE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists, only treat symptoms and do not address the underlying neurodegeneration. In addition to potentially improve the accuracy of diagnosis, biomarkers serve important roles for the development of putative disease-modifying drugs for AD. In this article, we review the existing and emerging areas of biomarker research and development for AD. Biochemical biomarkers in cerebrospinal fluid have been used to provide a link to disease pathology and may provide important proof of concept data for several classes of emerging therapeutics. Imaging biomarkers including volumetric magnetic resonance imaging and positron emission tomography assessing either glucose utilization or radioligands binding to amyloid plaque are discussed. Appropriate uses of these biomarkers in the context of the development of disease-modifying therapies are discussed. Drug Dev Res 70, 2009. © 2009 Wiley-Liss, Inc.

Ancillary